1. Stocks
    2. /
  2. BioNTech Se (NASDAQ: BNTX)
    3. /

BioNTech Se (NASDAQ: BNTX) Share Price and News

$86.71 $-1.38 (-1.6%) Friday, 26 April 2024 at 6:00:00 am Australian Eastern Standard Time

BioNTech Se Chart and Price Data

About BioNTech Se

Last updated 26-04-2024, 06:00:00am AEST
Current Price $86.71
Change $-1.38 (-1.6%)
Close Price $86.71
Open Price $87.98
Bid $86.13
Ask $88.17
Day Range $86.13 - $88.24
Year Range $85.21 - $125.83
Volume 438,099
Average Volume 602,425
Market Cap $20,613,221,500.00
Earnings Per Share $4.10

    • BioNTech Se (NASDAQ: BNTX)
    Latest News

    Share Market News

    Dow Jones hits new record highs. Are ASX 200 shares next?

    | Bernd Struben

    The Dow Jones just hit new all-time highs. ASX 200 shares are still 9% below their record highs, but that…

    Read more »

    Group of young friends wearing facemasks dining out and raising glasses in a toast
    Coronavirus News

    COVID-19 over? Credit and debit card spend surges

    | Tony Yoo

    Commonwealth Bank research shows Australians have started splashing the dollars around. Is the coronavirus recession over?

    Read more »

    A hand holding a pin about to burst a balloon, indicating a crash or drop in asx shares
    Share Market News

    Will Pfizer's COVID-19 vaccine end the ASX tech share rally?

    | Bernd Struben

    With Pfizer's announcement of a promising COVID-19 vaccine, ASX tech shares are largely missing out on the global share market…

    Read more »

    International Stock News

    Pfizer and BioNTech coronavirus vaccine accepted for rolling review in Canada

    | Eric Volkman

    Health Canada will determine BNT162b2's suitability for approval as clinical trial data comes in.

    Read more »

    person receiving coronavirus vaccine injection into the arm
    International Stock News

    3 reasons Pfizer and BioNTech will have coronavirus vaccine data before Moderna

    | Brian Orelli, PhD

    Different clinical trial designs gives the duo an advantage, but coming in first isn't the end goal for vaccine makers.

    Read more »

    doctor giving little boy vaccine injection in his arm
    International Stock News

    Johnson & Johnson (NYSE:JNJ) starts late-stage coronavirus vaccine clinical trial

    | Brian Orelli, PhD

    The phase 3 study of JNJ-78436735, which will enroll 60,000 participants, is underway.

    Read more »

    gloved hand injecting coronavirus vaccine into person's arm
    International Stock News

    Coronavirus vaccine trial adverse event was probably unrelated to treatment

    | Brian Orelli, PhD

    The paused clinical trial has already resumed.

    Read more »

    International Stock News

    Pfizer says it could know if its COVID-19 vaccine candidate works in October

    | Todd Campbell

    The drugmaker's CEO said there was a more than 60% chance that they would know by the end of next…

    Read more »

    doctor making thumbs up gesture and holding vial labelled 'covid-19 vaccine' representing covid shares
    International Stock News

    The surefire vaccine winner following AstraZeneca's COVID-19 trial pause

    | Keith Speights

    Hint: It's not Moderna.

    Read more »

    International Stock News

    What if more than one company wins the coronavirus vaccine race?

    | Alex Carchidi

    The ability to globally distribute a vaccine is as important as the vaccine itself. To the best-equipped victors go the…

    Read more »

    CSL share price represented by hand in blue glove picks out a vial labelled 'covid-19 vaccine' from a row of vials
    International Stock News

    Coronavirus vaccine race: 7 key things you'll want to know

    | Keith Speights

    Here are the answers to your top questions about where things stand with the development of COVID-19 vaccines.

    Read more »

    Patient wearing mask gets COVID vaccine injection
    International Stock News

    AstraZeneca coronavirus vaccine clinical trial paused

    | Brian Orelli, PhD

    One participant fell ill, but the connection to treatment with AZD122 is unclear.

    Read more »

    Profile

    since

    Note